A study found brain atrophy progresses more slowly with age in RRMS, highlighting the need to factor age into MS clinical ...

A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability ...

October 20, 2011 (Amsterdam, the Netherlands) — A new investigation finds that 6 years after diagnosis, brain volumes and, particularly, cognition were more severely affected in men with multiple ...

Decreases in daytime activity among adults with MS, indicated via accelerometers worn on their wrists, indicated later ...

Brain volume loss is a key marker of degeneration in multiple sclerosis, correlated with future disability progression. Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod significantly ...

After menopause, women with multiple sclerosis experienced accelerated volume loss in global gray matter, the left hippocampus, and the left anterior cingulate, highlighting the menopausal transition ...

A cross-sectional, prospective study found that gray matter atrophy was more prevalent in patients with more severe progressive multiple sclerosis (MS) compared with those with less severe progressive ...

As adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay diet went up, total grey matter decline and ...

Brain lesions — areas of brain tissue that show damage from injury or disease — are the biomarker most widely used to determine multiple sclerosis disease progression. But an innovative new study led ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...